Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 10:50 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 5,231 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Clear all
Completed No phase listed Observational

Outcomes of Anti-HIV Therapy During Early HIV Infection

NCT00001093
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Nov 1, 2026, 10:50 PM EST
Completed No phase listed Observational Results available

Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza

NCT01769430
View directory record Official record
Conditions
Influenza Virus Infection Transmission in Humans
Interventions
Observational Study of influenza aerosol shedding -- No Intervention
Other
Lead sponsor
University of Maryland, College Park
Other
Eligibility
10 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Nov 1, 2026, 10:50 PM EST
Completed Phase 3 Interventional

A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP

NCT00000700
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
28
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 1, 2026, 10:50 PM EST
Terminated Phase 2 Interventional Results available

An Extension of Protocol PRO 140_CD01 Study

NCT02355184
View directory record Official record
Conditions
HIV, Human Immunodeficiency Virus
Interventions
PRO 140 350mg weekly subcutaneous (SC) injection.
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Nov 1, 2026, 10:50 PM EST
Completed Phase 2 Interventional

A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

NCT00002399
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Posaconazole, Fluconazole
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 10:50 PM EST
Terminated Phase 2 Interventional Results available

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

NCT01928693
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Besivance 0.6% Ophthalmic Suspension, Zymaxid 0.5% Ophthalmic Solution, Vigamox 0.5% Ophthalmic Solution
Drug
Lead sponsor
Cornea Consultants Of Nashville
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Nov 1, 2026, 10:50 PM EST
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00117884
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Nov 1, 2026, 10:50 PM EST
Completed Not applicable Interventional Results available

Evaluation of Cellphone Based Otoscopy in Pediatric Patients

NCT04296448
View directory record Official record
Conditions
Ear Infection, Pediatric Disease, Acute Otitis Media
Interventions
Cellscope
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Nov 1, 2026, 10:50 PM EST
Not listed Phase 2 Interventional

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

NCT03719664
View directory record Official record
Conditions
HIV-1-infection
Interventions
Albuvirtide, 3BNC117, Baseline ART
Drug
Lead sponsor
Frontier Biotechnologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Nov 1, 2026, 10:50 PM EST
Terminated No phase listed Observational

Hepatitis C in Adults Who Underwent Congenital Heart Surgery Before Screening

NCT00359099
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1980 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Nov 1, 2026, 10:50 PM EST
Completed Phase 1 Interventional

Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study

NCT00646152
View directory record Official record
Conditions
Influenza, Severe Acute Respiratory Distress Syndrome, Smallpox, Ebola, Unknown Respiratory Viruses
Interventions
Poly-ICLC
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Nov 1, 2026, 10:50 PM EST
Completed Phase 2 Interventional Results available

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

NCT01526889
View directory record Official record
Conditions
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
Interventions
LFG316, Conventional Therapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
6
States / cities
Golden, Colorado • Marietta, Georgia • Cambridge, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Nov 1, 2026, 10:50 PM EST
Completed Not applicable Interventional

Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis

NCT00002010
View directory record Official record
Conditions
Meningitis, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Tucson, Arizona • San Diego, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 10:50 PM EST
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

NCT01590641
View directory record Official record
Conditions
Hepatitis B, HBV
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Nov 1, 2026, 10:50 PM EST
Terminated Phase 4 Interventional Results available

Hospital Avoidance Strategies for ABSSSI

NCT03372941
View directory record Official record
Conditions
Skin Infection
Interventions
Dalbavancin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Nov 1, 2026, 10:50 PM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Microalbuminuria in Children With and Without Diabetes

NCT00320086
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
6 Years to 18 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Nov 1, 2026, 10:50 PM EST
Completed Phase 2Phase 3 Interventional Results available

Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN

NCT00672854
View directory record Official record
Conditions
Parenteral Nutrition
Interventions
ClinOleic 20% Intravenous Emulsion, Intralipid, 20% Intravenous Emulsion
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Nov 1, 2026, 10:50 PM EST
Completed Phase 2 Interventional

A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

NCT00385502
View directory record Official record
Conditions
Onychomycosis
Interventions
EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
Drug
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Nov 1, 2026, 10:50 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions

NCT06911242
View directory record Official record
Conditions
Healthy Volunteer, Pharmacokinetics After Oral Intake
Interventions
ARN-75039
Drug
Lead sponsor
Arisan Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 1, 2026, 10:50 PM EST
Completed Phase 3 Interventional

A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy

NCT00000651
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
40
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Nov 1, 2026, 10:50 PM EST
Completed Not applicable Interventional

Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods

NCT02375477
View directory record Official record
Conditions
Bacterial Infection, Clostridium Difficile
Interventions
Educational Intervention
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Nov 1, 2026, 10:50 PM EST
Completed Phase 3 Interventional Results available

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

NCT01817075
View directory record Official record
Conditions
Bacterial Infection, Benign Neoplasm, Malignant Neoplasm, Methicillin-Resistant Staphylococcus Aureus Infection, Myeloid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
Chlorhexidine Gluconate Skin Cleanser, Laboratory Biomarker Analysis, Mild Soap Skin Cleanser, Questionnaire Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Months to 21 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
53
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Nov 1, 2026, 10:50 PM EST
Terminated Phase 2 Interventional Results available

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

NCT04126031
View directory record Official record
Conditions
Gram-negative Bacterial Infection
Interventions
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Days to 88 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Nov 1, 2026, 10:50 PM EST
Completed Phase 3 Interventional

A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo

NCT00002101
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
13 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Harbor City, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 10:50 PM EST